Compass Therapeutics : 2024 Proxy Supplemental
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy...
Stay updated with breaking news from Ellen Chiniara. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy...
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) had its price objective upped by Stifel Nicolaus from $35.00 to $55.00 in a report released on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 35.84% from the stock’s previous close. Other research analysts […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) traded down 1.9% during trading on Monday following insider selling activity. The stock traded as low as $36.22 and last traded at $36.49. 178,419 shares changed hands during trading, a decline of 80% from the average session volume of 883,645 shares. The stock had previously closed at […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Kymera Therapeutics in a research report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.79) per share for the quarter. Leerink Partnrs currently has […]
Operator: Hello, and welcome to the Kymera Therapeutics Fourth Quarter 2022 Earnings Conference Call. Please note, this event is being recorded.